News

Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are ...
European pharmaceutical stocks have swooned while the broader market has climbed higher. As a result, stocks in the sector ...
Ongoing patent battle between Novo Nordisk and Dr Reddy’s Laboratories over semaglutide export to multiple countries.
Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing ...
Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...
What happens when you stop taking Ozempic®? There’s no one-size-fits-all answer to this question. When you stop taking ...
After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic versions of Novo Nordisk’s lucrative semaglutide drugs for diabetes and obesi | ...
An NHS surgeon has delivered his 'hot take' on why weight-loss jabs like Wegovy and Mounjaro are causing 'Ozempic babies' to be born.
Novo Nordisk trades at a significant discount to Eli Lilly, offering nearly 38% upside. Click here to find out why NVO stock is a Buy.
The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...